Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

ER mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

ER-CCDC170 fusion (3)

ER-CCDC170 fusion (3)

›

Related tests:

Guardant360® CDx (54)

Guardant360® CDx (54)

ER mutation	Estrogen Receptor Positive Breast Cancer	ER mutation	Estrogen Receptor Positive Breast Cancer	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B
ER mutation	Breast Cancer	ER mutation	Breast Cancer	palbociclib Resistant: B - Late Trials palbociclib Resistant : B	palbociclib Resistant: B - Late Trials palbociclib Resistant : B
ER mutation	Hormone Receptor Positive Breast Cancer	ER mutation	Hormone Receptor Positive Breast Cancer	exemestane Resistant: B - Late Trials exemestane Resistant : B	exemestane Resistant: B - Late Trials exemestane Resistant : B
ER mutation	Estrogen Receptor Positive Breast Cancer	ER mutation	Estrogen Receptor Positive Breast Cancer	fulvestrant Sensitive: B - Late Trials fulvestrant Sensitive : B	fulvestrant Sensitive: B - Late Trials fulvestrant Sensitive : B
ER mutation	Estrogen Receptor Positive Breast Cancer	ER mutation	Estrogen Receptor Positive Breast Cancer	exemestane Resistant: B - Late Trials exemestane Resistant : B	exemestane Resistant: B - Late Trials exemestane Resistant : B
ER mutation	Hormone Receptor Positive Breast Cancer	ER mutation	Hormone Receptor Positive Breast Cancer	fulvestrant Sensitive: B - Late Trials fulvestrant Sensitive : B	fulvestrant Sensitive: B - Late Trials fulvestrant Sensitive : B
ER mutation	HER2 Negative Breast Cancer	ER mutation	HER2 Negative Breast Cancer	Aromatase inhibitor + palbociclib Resistant: B - Late Trials Aromatase inhibitor + palbociclib Resistant : B	Aromatase inhibitor + palbociclib Resistant: B - Late Trials Aromatase inhibitor + palbociclib Resistant : B
ER mutation	Breast Cancer	ER mutation	Breast Cancer	fulvestrant Sensitive: C2 – Inclusion Criteria fulvestrant Sensitive : C2	fulvestrant Sensitive: C2 – Inclusion Criteria fulvestrant Sensitive : C2
ER mutation	Estrogen Receptor Positive Breast Cancer	ER mutation	Estrogen Receptor Positive Breast Cancer	elacestrant Sensitive: C2 – Inclusion Criteria elacestrant Sensitive : C2	elacestrant Sensitive: C2 – Inclusion Criteria elacestrant Sensitive : C2
ER mutation	HER2 Negative Breast Cancer	ER mutation	HER2 Negative Breast Cancer	GDC-9545 Sensitive: C2 – Inclusion Criteria GDC-9545 Sensitive : C2	GDC-9545 Sensitive: C2 – Inclusion Criteria GDC-9545 Sensitive : C2
ER mutation	HER2 Negative Breast Cancer	ER mutation	HER2 Negative Breast Cancer	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3
ER mutation	Breast Cancer	ER mutation	Breast Cancer	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3
ER mutation	Estrogen Receptor Positive Breast Cancer	ER mutation	Estrogen Receptor Positive Breast Cancer	enobosarm Sensitive: C3 – Early Trials enobosarm Sensitive : C3	enobosarm Sensitive: C3 – Early Trials enobosarm Sensitive : C3
ER mutation	HER2 Negative Breast Cancer	ER mutation	HER2 Negative Breast Cancer	SAR439859 Sensitive: C3 – Early Trials SAR439859 Sensitive : C3	SAR439859 Sensitive: C3 – Early Trials SAR439859 Sensitive : C3
ER mutation	HER2 Negative Breast Cancer	ER mutation	HER2 Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3
ER mutation	Hormone Receptor Positive Breast Cancer	ER mutation	Hormone Receptor Positive Breast Cancer	alpelisib Resistant: C3 – Early Trials alpelisib Resistant : C3	alpelisib Resistant: C3 – Early Trials alpelisib Resistant : C3
ER mutation	Estrogen Receptor Positive Breast Cancer	ER mutation	Estrogen Receptor Positive Breast Cancer	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3
ER mutation	HER2 Negative Breast Cancer	ER mutation	HER2 Negative Breast Cancer	G1T48 Sensitive: C4 – Case Studies G1T48 Sensitive : C4	G1T48 Sensitive: C4 – Case Studies G1T48 Sensitive : C4